| P50 | author | Karla Kirkegaard | Q63441905 |
| P2093 | author name string | Christopher D Richardson | |
| | Timothy L Tellinghuisen | |
| | Nicholas van Buuren | |
| P2860 | cites work | Exploiting Genetic Interference for Antiviral Therapy | Q24288775 |
| | Viral mutation rates | Q24611162 |
| | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| | Kinetic and structural analyses of hepatitis C virus polyprotein processing | Q24648164 |
| | Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates | Q24812175 |
| | Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication | Q27339861 |
| | Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase | Q27473147 |
| | General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2'-Modified Nucleotide Analogues | Q27477760 |
| | Superinfection Exclusion in Cells Infected with Hepatitis C Virus | Q27478378 |
| | Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral Genomes | Q27480348 |
| | Production of infectious hepatitis C virus in tissue culture from a cloned viral genome | Q27860899 |
| | Complete replication of hepatitis C virus in cell culture | Q27860934 |
| | My Cousin, My Enemy: quasispecies suppression of drug resistance | Q28076138 |
| | The lipid droplet is an important organelle for hepatitis C virus production | Q28131709 |
| | Hepatitis C virus RNA replication depends on specific cis- and trans-acting activities of viral nonstructural proteins | Q28546101 |
| | Coordination of Hepatitis C Virus Assembly by Distinct Regulatory Regions in Nonstructural Protein 5A | Q28551959 |
| | An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus | Q29614207 |
| | Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 |
| | Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 |
| | Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection | Q29620318 |
| | Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 |
| | The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation | Q33727091 |
| | Mutational and fitness landscapes of an RNA virus revealed through population sequencing | Q33953331 |
| | Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect | Q34022149 |
| | Permissive secondary mutations enable the evolution of influenza oseltamivir resistance | Q34118992 |
| | A disulfide-bonded dimer of the core protein of hepatitis C virus is important for virus-like particle production | Q34120119 |
| | Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures. | Q34185327 |
| | Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052 | Q34185949 |
| | Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance | Q34261616 |
| | Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication | Q34430077 |
| | Dominant drug targets suppress the emergence of antiviral resistance | Q34729490 |
| | Suppression of Drug Resistance in Dengue Virus | Q36431588 |
| | Virus mutation frequencies can be greatly underestimated by monoclonal antibody neutralization of virions. | Q36832010 |
| | HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. | Q37447762 |
| | Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. | Q37699395 |
| | Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application | Q37700067 |
| | Novel therapies for hepatitis C - one pill fits all? | Q38117549 |
| | Antiviral activity and resistance of HCV NS5A replication complex inhibitors | Q38125035 |
| | Combining oncolytic virotherapy and cytotoxic therapies to fight cancer | Q38262391 |
| | Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of the Viral Genome to Assembly Sites | Q38727055 |
| | Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A. | Q38822088 |
| | The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. | Q38846227 |
| | NS5A Domain 1 and Polyprotein Cleavage Kinetics Are Critical for Induction of Double-Membrane Vesicles Associated with Hepatitis C Virus Replication | Q38855634 |
| | Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review | Q38893244 |
| | HCV NS5A replication complex inhibitors | Q38958434 |
| | Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers. | Q39138235 |
| | Genetically altering the thermodynamics and kinetics of hepatitis B virus capsid assembly has profound effects on virus replication in cell culture | Q39217491 |
| | The Coding Region of the HCV Genome Contains a Network of Regulatory RNA Structures | Q39999002 |
| | Cell culture and infection system for hepatitis C virus | Q40150021 |
| | The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture | Q40346087 |
| | Efficient rescue of hepatitis C virus RNA replication by trans-complementation with nonstructural protein 5A. | Q40478178 |
| | Dominant negative effect of wild-type NS5A on NS5A-adapted subgenomic hepatitis C virus RNA replicon | Q40541514 |
| | L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. | Q40896732 |
| | The interface between hepatitis B virus capsid proteins affects self-assembly, pregenomic RNA packaging, and reverse transcription | Q41610650 |
| | Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials | Q42173527 |
| | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study | Q42202756 |
| | Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | Q42225540 |
| | A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle | Q42546287 |
| | In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms | Q42982898 |
| | HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus | Q45843803 |
| | Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses | Q46555479 |
| | Daclatasvir plus sofosbuvir for HCV infection. | Q51846279 |
| | Detection and Differentiation of Multiple Viral RNAs Using Branched DNA FISH Coupled to Confocal Microscopy and Flow Cytometry. | Q64896239 |
| | Complete three-dimensional structures of picornaviral RNA-dependent RNA polymerases | Q80421564 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis C virus | Q708693 |
| P577 | publication date | 2018-03-28 | |
| P1433 | published in | eLife | Q2000008 |
| P1476 | title | Transmission genetics of drug-resistant hepatitis C virus | |
| P478 | volume | 7 | |